On March 15, 2021 Mission Therapeutics ("Mission"), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), reported that Paul Thompson, Chief Scientific Officer, will present at the Targeted Protein Degradation Europe Summit (16-18 March) (Press release, Mission Therapeutics, MAR 15, 2021, View Source [SID1234576650]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Paul Thompson will present on 18 March at 14:05 GMT, discussing how deubiquitylating (DUB) enzymes can be targeted for the treatment of human diseases. As an example, Paul will examine Mission’s lead in-house DUB inhibitor target, USP30.

The Targeted Protein Degradation Europe Summit was created with the goal of accelerating the translation of selective bioavailable and effective protein degraders into clinical trials. The Summit provides a platform of learning, discovery, and networking opportunities, to hear about the latest developments and advancements, and get invaluable guidance from leaders in the field of protein degradation. The event brings together over 100 biopharmaceutical professionals to capitalise on this emerging therapeutic class and make targeted protein degradation a blockbuster therapeutic approach that improves patient outcomes.